[Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
作者信息
Rosenthal J, Jaeger H, Specker M
出版信息
Arzneimittelforschung. 1979;29(9):1428-32.
PMID:583254
Abstract
By the US Food and Drug Administration spironolactone is regarded as a drug with problems related to bioavailability. A steady-state study was performed comparing the 50- and 100-mg formulations of two manufacturers with each other. Applying a fluorimetric method to both canrenone and canrenoate--the major biologically active metabolites of spironolactone--the two brands were compared in 11 volunteers for the 50 mg, and in 10 volunteers for the 100 mg dosage form.
摘要
相似文献
1
[Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
Arzneimittelforschung. 1979;29(9):1428-32.
2
[Bioavailability studies of two spironolactone-preparations (author's transl)].
Arzneimittelforschung. 1981;31(9):1498-503.
3
Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.雅培 ARCHITECT 临床化学和免疫分析系统：地高辛检测不受螺内酯、坎利酮及其常见代谢产物坎利酮的干扰。
Ther Drug Monit. 2011 Feb;33(1):128-31. doi: 10.1097/FTD.0b013e3181fd4c30.
4
[Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].苄氟噻嗪与螺内酯联合应用的药代动力学研究及生物利用度
Arzneimittelforschung. 1986 Mar;36(3):490-5.
5
[Comparative bioavailability of two forms of spironolactone. Rationalization applied to dosage (author's transl)].两种形式螺内酯的比较生物利用度。剂量合理化应用（作者译）
Therapie. 1981 Jul-Aug;36(4):443-9.
6
Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.螺内酯、坎利酸钾及其共同代谢产物坎利酮对采用新型地高辛免疫分析法地高辛III测定血清地高辛的影响。
Ther Drug Monit. 2008 Dec;30(6):744-7. doi: 10.1097/FTD.0b013e31818b0e6a.
7
[Biological availability of spironolactone in two different galenic forms (author's transl)].螺内酯两种不同剂型的生物利用度（作者译）
Dtsch Med Wochenschr. 1979 Jun 15;104(24):881-3. doi: 10.1055/s-0028-1104007.
8
Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.验证血浆和尿中坎利酮用于测定螺内酯生物利用度——片剂与溶液/混悬液的比较
Int J Clin Pharmacol Biopharm. 1977 May;15(5):205-10.
9
[Studies of biological availability. A critical assessment based on a study of spironolactone preparations].
Wien Med Wochenschr. 1988 Apr 15;138(6-7):156-60.
10
Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.代谢物分析——螺内酯制剂生物等效性研究的新方法。
Int J Clin Pharmacol Ther. 1997 Aug;35(8):334-40.
Zotero 插件